Compare · GIA vs LIVN
GIA vs LIVN
Side-by-side comparison of GigCapital 5 Inc. (GIA) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GIA and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.43B, about 15.1x GIA ($292.5M).
- LIVN has more recent analyst coverage (20 ratings vs 0 for GIA).
- Company
- GigCapital 5 Inc.
- LivaNova PLC
- Price
- $3.62-13.81%
- $80.52+3.03%
- Market cap
- $292.5M
- $4.43B
- 1M return
- -
- -0.62%
- 1Y return
- -
- +85.26%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 20
GigCapital 5 Inc.
GigCapital5, Inc. is a blank check company. The company was incorporated in 2021 and is based in Palo Alto, California.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest GIA
- Catalyze Partners Appoints Raanan Horowitz to Board of Advisors
- SEC Form 8-K filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- GigCapital 5 Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Budagov Stas
- SEC Form 3 filed by new insider Weiner Zeev
- SEC Form 3 filed by new insider Dickson Daniel
- SEC Form 3 filed by new insider Taylor Ross
- GigCapital 5 Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Latest LIVN
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)